• Pituitary disorders

Egrifta Generic Name & Formulations

General Description

Tesamorelin 1mg; per vial; lyophilized pwd for SC inj after reconstitution; preservative-free; contains mannitol.

Pharmacological Class

Growth hormone releasing factor analogue.

See Also

How Supplied

Egrifta—60 (vials w. diluent + supplies); Egrifta SV—30 (vials w. diluent + supplies)


Generic Availability


Egrifta Indications


For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Limitations of Use

Long-term cardiovascular benefit and safety have not been studied. Not for use in weight loss management. No data to support improved compliance with anti-retroviral therapies in HIV (+) patients.

Egrifta Dosage and Administration


Give by SC inj. Inject into abdomen, rotate inj sites. 2mg once daily.


Not established.

Egrifta Contraindications


Disruption of hypothalmic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumors/surgery, head irradiation, or head trauma. Active malignancy. Pregnancy.

Egrifta Boxed Warnings

Not Applicable

Egrifta Warnings/Precautions


History of treated and stable malignancies. Fluid retention. Discontinue in critically ill patients. Monitor IGF-1 levels closely; consider discontinuing if IGF-1 levels persistently elevated (eg, >3 SDS). Increased risk of impaired glucose tolerance or diabetes; monitor for changes in glucose metabolism. Monitor for worsening retinopathy in diabetic patients. Nursing mothers: not recommended.

Egrifta Pharmacokinetics

See Literature

Egrifta Interactions


Caution with concomitant drugs metabolized by CYP450 (eg, corticosteroids, sex steroids, anticonvulsants, cyclosporine). May inhibit 11β-hydroxysteroid dehydrogenase type 1; may need to increase maintenance and stress doses of glucocorticoid if needed for replacement in hypoadrenalism.

Egrifta Adverse Reactions

Adverse Reactions

Arthralgia, inj site erythema/pruritus, extremity pain, peripheral edema, hyperglycemia, myalgia, carpal tunnel syndrome; glucose intolerance, hypersensitivity reactions.

Egrifta Clinical Trials

See Literature

Egrifta Note

Not Applicable

Egrifta Patient Counseling

See Literature